The economic model that has underpinned the development of drug products for decades is currently under siege. Faced on one side with mounting pressure from payers to address affordability issues, pharmaceutical companies are facing ever more stringent regulatory requirements alongside … Read More
clinical trials
One size fails all? The weight of evidence for personalized dosing in oral GLP-1 therapies
In recent years, the pharmaceutical industry has borne witness to the meteoric rise of glucagon-like peptide-1 receptor agonist (GLP-1) therapies. Having fast become established as a potentially life-changing treatment for Type 2 diabetes and obesity, emerging evidence of the cardio and … Read More
The Importance of Dose Optimisation in Oncology Clinical Trials
Let us first recognise the enormity of the challenges we are facing, on a global scale, when it comes to cancer. It is estimated that there were 18.1 million new cases of cancer worldwide in 2020, with around 10 million … Read More
Innovative Approaches to Enhance and Measure Medication Adherence in Chronic Disease Management
Medication adherence is a vital component in managing chronic diseases effectively. However, it remains a significant challenge, with non-adherence rates reaching up to 50% among patients. This lack of adherence results in poor health outcomes and increased burdens on healthcare … Read More
AARDEX and Schreiner MediPharm reinforce their collaboration to Enhance Medication Adherence Management
AARDEX Group and Pill Connect Ltd Partner to Empower Patient Adherence … Read More
AARDEX Group and Pill Connect Ltd Partner to Empower Patient Adherence
AARDEX Group and Pill Connect Ltd Partner to Empower Patient Adherence … Read More
A Digital Innovation for the Personalized Management of Adherence
Bernard Vrijens our CEO and Scientific Lead, and Anna-Elisa Hein realizing a master thesis placement at AARDEX Group, conducted a study analyzing the strengths, weaknesses, threats, and opportunities of digital innovation for the personalized management of medication adherence. Anna-Elisa interviewed … Read More
We see an uptake in Remote, Decentralized and Hybrid Trials. Do you?
We are soon leaving a very difficult year in all aspects. We lived with global pandemic and civil troubles in the news all year long. However, our Scientific Lead, Bernard Vrijens sees an uptake in remote, decentralized, and hybrid trials. … Read More
ONdrugDelivery October Issue is now live which includes a contribution of AARDEX Group
AARDEX’s Scientific Lead Bernard Vrijens and Biocorp’s business development director Arnaud Guillet give some details about their companies alliance. They explain how Biocorp’s Injay connected prefilled syringe (PFS) combined with AARDEX’s MEMS Adherence Software provides a mean to tackle the … Read More
The Contract Pharma October Issue is now live which includes an article about AARDEX Group
Medication adherence, which involves patients taking medications in accordance with how they have been prescribed, is a widespread challenge, with wide-reaching implications for patients and health services worldwide. Managing patient compliance can make the difference between failed and successful clinical … Read More